RAND estimates millions of Americans microdosed psychedelics in 2025 plus US state policy updates on psilocybin

RAND estimates around 10 million U.S. adults microdosed psychedelics in 2025, based on a nationally representative survey scaled to the total adult population. The newsletter summarizes what people reported using: psilocybin (including mushrooms and synthetic) was most common, followed by MDMA and then Amanita muscaria. It also notes that Amanita products are often marketed in edibles, with concerns they may be mislabeled. The issue then covers U.S. psychedelics policy developments, including New Jersey committing $6 million to a two-year psilocybin research pilot and additional state bill activity in New Hampshire, Iowa, and Washington State. It also highlights New Mexico’s upcoming psilocybin program advisory board committees, including patient safety, dosing and clinical practice, education and training, harm reduction, propagation, equity and access, and end-of-life considerations.